Skip Nav Destination
Issues
1 August 2010
-
Cover Image
Cover Image
Genetically-engineered mouse models often represent some of the most physiologically accurate models of cancer from which to understand the tumor microenvironment and with which to perform preclinical trials; however, tumors are often deep-seated and small animal imaging is a requisite for detecting and studying tumor progression. Presented on the cover is an example of multiplex optical and near-infrared imaging of a metastatic childhood rhabdomyosarcoma mouse model showing viable tumor cells in the left lower leg by firefly luciferase luminescence (green channel), pooling of an IR-820 dye due to loss of capillary integrity (red channel), and metal metalloprotease biochemical activity using a biochemically-activated contrast agent (blue channel). For details, see article by Schaffer and colleagues on page 2354. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Therapeutic Discovery
γ-Tocotrienol Promotes TRAIL-Induced Apoptosis through Reactive Oxygen Species/Extracellular Signal-Regulated Kinase/p53–Mediated Upregulation of Death Receptors
Ramaswamy Kannappan; Jayaraj Ravindran; Sahdeo Prasad; Bokyung Sung; Vivek R. Yadav; Simone Reuter; Madan M. Chaturvedi; Bharat B. Aggarwal
Preclinical Development
Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
Clara Albanese; Rachele Alzani; Nadia Amboldi; Nilla Avanzi; Dario Ballinari; Maria Gabriella Brasca; Claudio Festuccia; Francesco Fiorentini; Giuseppe Locatelli; Wilma Pastori; Veronica Patton; Fulvia Roletto; Francesco Colotta; Arturo Galvani; Antonella Isacchi; Jurgen Moll; Enrico Pesenti; Ciro Mercurio; Marina Ciomei
Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer
Savita Bisht; Masamichi Mizuma; Georg Feldmann; Niki A. Ottenhof; Seung-Mo Hong; Dipankar Pramanik; Venugopal Chenna; Collins Karikari; Rajni Sharma; Michael G. Goggins; Michelle A. Rudek; Rajani Ravi; Amarnath Maitra; Anirban Maitra
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry; Timothy Guzi; Frances Shanahan; Nicole Davis; Deepa Prabhavalkar; Derek Wiswell; Wolfgang Seghezzi; Kamil Paruch; Michael P. Dwyer; Ronald Doll; Amin Nomeir; William Windsor; Thierry Fischmann; Yaolin Wang; Martin Oft; Taiying Chen; Paul Kirschmeier; Emma M. Lees
Immune Competency of a Hairless Mouse Strain for Improved Preclinical Studies in Genetically Engineered Mice
Beverly S. Schaffer; Marcia H. Grayson; Joy M. Wortham; Courtney B. Kubicek; Amanda T. McCleish; Suresh I. Prajapati; Laura D. Nelon; Michelle M. Brady; Inkyung Jung; Tohru Hosoyama; Leslea M. Sarro; Martha A. Hanes; Brian P. Rubin; Joel E. Michalek; Charles B. Clifford; Anthony J. Infante; Charles Keller
Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma
Whitney A. Spannuth; Lingegowda S. Mangala; Rebecca L. Stone; Amy R. Carroll; Masato Nishimura; Mian M.K. Shahzad; Sun-Joo Lee; Myrthala Moreno-Smith; Alpa M. Nick; Ren Liu; Nicholas B. Jennings; Yvonne G. Lin; William M. Merritt; Robert L. Coleman; Pablo E. Vivas-Mejia; Yue Zhou; Valery Krasnoperov; Gabriel Lopez-Berestein; Parkash S. Gill; Anil K. Sood
Molecular Medicine in Practice
Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth
Josette Carnahan; Pedro J. Beltran; Carol Babij; Quynh Le; Mark J. Rose; Steven Vonderfecht; Joseph L. Kim; Adrian L. Smith; Karthik Nagapudi; Martin A. Broome; Manory Fernando; Hue Kha; Brian Belmontes; Robert Radinsky; Richard Kendall; Teresa L. Burgess
Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary
Seiji Mabuchi; Chiaki Kawase; Deborah A. Altomare; Kenichirou Morishige; Masami Hayashi; Kenjiro Sawada; Kimihiko Ito; Yoshito Terai; Yukihiro Nishio; Andres J. Klein-Szanto; Robert A. Burger; Masahide Ohmichi; Joseph R. Testa; Tadashi Kimura
Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer
Marianne K. Melnik; Craig P. Webb; Patrick J. Richardson; Charles R. Luttenton; Alan D. Campbell; Thomas J. Monroe; Timothy J. O'Rourke; Kathleen J. Yost; Connie M. Szczepanek; Michelle R. Bassett; Kimberly J. Truszkowski; Phyllis Stein; Matthew W. Van Brocklin; Alan T. Davis; Gabriela Bedolla; George F. Vande Woude; Han-Mo Koo
Letters to the Editor
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.